Identification of an antibody‐based immunoassay for measuring direct target binding of RIPK1 inhibitors in cells and tissues

Therapies that suppress RIPK1 kinase activity are emerging as promising therapeutic agents for the treatment of multiple inflammatory disorders. The ability to directly measure drug binding of a RIPK1 inhibitor to its target is critical for providing insight into pharmacokinetics, pharmacodynamics,...

Descripción completa

Detalles Bibliográficos
Autores principales: Finger, Joshua N., Brusq, Jean‐Marie, Campobasso, Nino, Cook, Michael N., Deutsch, Jennifer, Haag, Heather, Harris, Philip A., Jenkins, Earl L., Joglekar, Devika, Lich, John D., Maguire, Sean, Nagilla, Rakesh, Rivera, Elizabeth J., Sun, Helen, Votta, Bartholomew J., Bertin, John, Gough, Peter J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5723705/
https://www.ncbi.nlm.nih.gov/pubmed/29226625
http://dx.doi.org/10.1002/prp2.377

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5723705/
https://www.ncbi.nlm.nih.gov/pubmed/29226625
http://dx.doi.org/10.1002/prp2.377

Ejemplares similares